Over Expression of HER2/Neu in Female Ductal Carcinoma: Pure Invasive Versus Invasive with in Situ Component
Journal of Surgery
Volume 2, Issue 6, December 2014, Pages: 105-108
Received: Dec. 9, 2014;
Accepted: Dec. 19, 2014;
Published: Dec. 27, 2014
Views 2438 Downloads 115
Mohamed Salah Abdelhamid, Bani Suef Faculty of Medicine, Bani Suef University, Egypt
Ahmed Mohamed Sadat, Bani Suef Faculty of Medicine, Bani Suef University, Egypt
Mohamed Salah Abdelbasset, Bani Suef Faculty of Medicine, Bani Suef University, Egypt
Amr Mohamed Aly Mohamed, Bani Suef Faculty of Medicine, Bani Suef University, Egypt
Hesham y Ahmed Abdel Wahab Nafad, Bani Suef Faculty of Medicine, Bani Suef University, Egypt
Khald Mohamed Shawky, Bani Suef Faculty of Medicine, Bani Suef University, Egypt
Solafa Amin Abdelaziz, Kasr El Aini Faculty of Medicine, Cairo University, Egypt
Lobna Omar El Farouk Abd Elsalam, Kasr El Aini Faculty of Medicine, Cairo University, Egypt
Mahmoud Ahmed Negida, Kasr El Aini Faculty of Medicine, Cairo University, Egypt
Reham Shehab El Nemr Esmail, National Research Center, Cairo University, Egypt
Adel Morad Abdellah, October 6th Faculty of Medicine, October 6th University, Cairo, Egypt
Ahmed Zaki Gharib, October 6th Faculty of Medicine, October 6th University, Cairo, Egypt
Aims: We are trying to understand the role of HER 2 neu in tumor progression. Study design: Prospective study. Place and duration: Conducted at Bani Swif and Kasr AL Aini university hospitals between May 2013 and May 2014. Methodology: 32 patients were enrolled in the study. The speceimens were obtained surgically .Expression of HER-2-neu receptors done aided with Dako Code No. A0485. Results: In the study there were 15 cases with pure invasive carcinoma and 17 cases with in situ component , there were more positive cases (59%) with HER-2-neu in the invasive associated with in situ group than those in the pure invasive group (20%), this was statistically significant (P<0.016). Conclusion: In conclusion, it may be assumed that during cells of the in situ component are acquiring invasiveness, they partly loose Her-2-neu over expression The high percent of positive HER-2-neu in cases associated with in situ component point an arrow with question mark towards possible changes in the tumor cell biology or the actual cell line of the in situ and the invasive components.
Mohamed Salah Abdelhamid,
Ahmed Mohamed Sadat,
Mohamed Salah Abdelbasset,
Amr Mohamed Aly Mohamed,
Hesham y Ahmed Abdel Wahab Nafad,
Khald Mohamed Shawky,
Solafa Amin Abdelaziz,
Lobna Omar El Farouk Abd Elsalam,
Mahmoud Ahmed Negida,
Reham Shehab El Nemr Esmail,
Adel Morad Abdellah,
Ahmed Zaki Gharib,
Over Expression of HER2/Neu in Female Ductal Carcinoma: Pure Invasive Versus Invasive with in Situ Component, Journal of Surgery.
Vol. 2, No. 6,
2014, pp. 105-108.
Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl) 1997; 14:429–439. doi: 10.1007/s001090050128. [PubMed] [Cross Ref]
Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res. 1997; 14:4368–4377. [PubMed]
Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan C, Polyak K. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 2006; 14:4065–4078. doi: 10.1158/0008-5472.CAN-05-4083.[PubMed] [Cross Ref]
Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007;14:11565–11575. doi: 10.1158/0008-5472.CAN-07-2536. [PubMed] [Cross Ref]
Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, Dezso Z, Mulvey L, Macconaill LE, Winckler W, Serebryiskaya T, Nikolskaya T, Polyak K. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008;14:9532–9540. doi: 10.1158/0008-5472.CAN-08-3082. [PubMed] [Cross Ref]
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993; 14:4960–4970. [PubMed]
Grosvor CE and Picciano FC.: Hormones and growth factors milk. Endo Rev, 61:413-17, 1993.
Vonderhaar BK.: Regulation of development of mammary gland. Cancer treat Res, 40:551-559, 1988.
Daly JM, Bertagnolli M, Decosse JJ, et al.: Oncology. In Schwartz SI (ed) Principles of Surgery.: New York, MC Grow-Hill, pp 297-360, 7th ed, 1999.
Cianfrocca M and Goldstein LJ.: Prognostic and predictive factors in early stage breast cancer. The oncologist, 2004, 9 (6):606-616.
Weiss LM.: Breast, in Weidner N, Cote RJ, Susters and Weiss LM (eds) Modern Surgical Pathology.: Philadelphia, Saunders pp 599-672, 1st ed, 2003.
Koeppen HKW, Wright BD, Burt AD, et al.: Over expression of HER-2-neu an immunohistochemical survey. Histopathology, 38:96-104, 2001.
Swinscow TDV and Campell MJ.: statistics at square one. In Swinscow TDV (ed) Plymouth Latimer trend Company Ltd, pp 1-139 9th ed, 1996.
Schmitt FC, Figueiredo P and Lacarda M.: Exxpression of C-erb B-2 protein and DNA ploidy in breast carcinogenesis. Arch Path Lab Med, 119 (9):815-20, 1995. Breast Cancer Res. 2012; 14(4): R115.
Jang MH,Kim EJ, Choi Y ,Lee HE ,Kim YJ ,Kim JH ,Kang E, Kim SW , Kim IA , and Park SY .FGFR1 is amplified during the progression of in situ to invasive breast carcinoma Published online Aug 3, 2012. doi: 10.1186/bcr3239
Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002; 14:1318–1325. doi: 10.1097/01.MP.0000038462.62634.B1. [PubMed] [Cross Ref]
Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2006; 14:702–707. doi: 10.1111/j.1365-2559.2006.02403.x. [PubMed] [Cross Ref]
Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006; 14:135–144. doi: 10.1007/s10549-005-9101-z. [PubMed][Cross Ref]
Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery JP, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Delattre O. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008; 14:1956–1965. doi: 10.1158/1078-0432.CCR-07-1465. [PubMed] [Cross Ref]
Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999; 14:396–402. doi: 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L. [PubMed] [Cross Ref]
Hwang ES, DeVries S, Chew KL, Moore DH, Kerlikowske K, Thor A, Ljung BM, Waldman FM. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004; 14:5160–5167. doi: 10.1158/1078-0432.CCR-04-0165. [PubMed] [Cross Ref]
Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'Hern R, Marchio C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012; 14:42–52. doi: 10.1002/path.3990. [PubMed] [Cross Ref]